Accession Number: | 0001104659-23-007998 |
Date: | 2023-01-26 |
Issuer: | Y-MABS THERAPEUTICS, INC. (YMAB) |
Original Submission Date: |
SMITH SUSAN LAURA
C/O Y-MABS THERAPEUTICS, INC.
230 PARK AVENUE SUITE 3350
NEW YORK, NY 10169
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
EMPLOYEE STOCK OPTION (RIGHT TO BUY) | 4.55 | 2023-01-26 | deemed execution date | A | 32,000 (a) | 2033-01-26 | common stock 32,000 | $4.55 | 32,000 | direct |
ID | footnote |
---|---|
f1 | stock options granted to the reporting person pursuant to the 2018 equity incentive plan of y-mabs therapeutics, inc. |
f2 | the stock option shall vest and become exercisable as to 25% of the shares subject to the option on january 26, 2024, and thereafter vests and become exercisable as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the reporting person on each vesting. |